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Abstract
J MIELKE
This review is confined to the drug management o f chronic pain, and is specifically adapted to the resource- 
poor environment and the HIV pandemic of sub-Saharan Africa. A brief classification of chronic pain is 
followed by a discussion of the different classes of medications in use, including those used in migraine. An 
approach to the rational drug management o f neuropathic pain is presented. In conclusion some general
principles for prescribing in this setting are derived.
Introduction
The patient with intractable chronic pain (such as low 
back pain, headache, 'rheumatism' or burning feet) is 
well known to all primary care physicians, and to most 
specialists. He or she is the 'heartsink patient', who will 
take up precious time, yet again going through the same 
symptoms which never improve, and which feel like a 
catalogue o f the physician's failures. “Yes, you tried 
that it never did a thing,” is a recurring theme, evoking
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profound apprehension and anxiety in the doctor when 
he sees the familiar face in his waiting room. Effective 
treatment, and above all a consistent plan of action in 
dealing with such unfortunate people is much needed.
Chronic pain has been shown to affect at least one 
adult in five in Europe,1 and serious and time- 
consuming. More than cancer or heart disease, painful 
conditions including osteoarthritis and back pain have 
the largest negative impact on quality of life o f all 
chronic conditions for people living in the community.2
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Experts in pain management, and standard textbooks 
on the subject, emphasise the multidisciplinary nature 
o f  the field. They point out that many different 
modalities o f treatment are available, including 
psychological support, physical therapy, relaxation 
therapy, surgical interventions, nerve blocks, 
occupational interventions and counselling services. 
In sophisticated centres such multifaceted teams do 
often improve their patients' quality o f life after years 
o f suffering. However, for the majority o f patients 
access to dedicated pain clinics is unrealistic, and the 
primary care physician needs to be in straight forward 
review o f commonly used medications is presented 
here, without reference to the many other available 
modalities.
Pain Subtypes.
At this juncture, it will be helpful to review the 
classification o f pain. Practically, it is important to 
decide whether a particular patient's pain is nociceptive 
(from a noxious stimulus), neuropathic (because of 
injury in the nervous system) or psychogenic (without 
structural or other organic damage). Examples o f 
'simple' nociceptive pain are post operative pain, 
mechanical low back pain, sports injuries or arthritis. 
Examples o f neuropathic pain include post herpetic 
neuralgia, radicular pain from root compression 
because o f a prolapsed intervertebral disc, painful 
neuropathy and trigeminal neuralgia. Psychogenic 
pain is often atypical, bizarre (“my scalp feels like it is 
bubbling”) and non-anatomical in distribution. It may 
accompany or complicate other pain types.
' Simple' Analgesics.
Paracetamol and prostaglandin inhibitors (including 
cyclo-oxygenase 2 [COX-2] inhibitors) are often 
referred to as simple analgesics, and include many 
commonly used anti-infammatories, such as aspirin, 
ibuprofen, mefenamic acid, indomethacin, piroxicam 
and diclofenac. They all exhibit effectiveness in 
nociceptive pain, but do have different side effects and 
toxicities.
Aspirin is unsuitable under the age o f 12 years because 
of the risk of Reye's syndrome, but is excellent for pain 
o f noxious types, especially inflammatory, in adults. 
Chronic use in high doses is limited by gastric irritation 
and the risk o f interstitial nephritis. It may be a 
powerful adjunct in treating pain from bony and other 
metastases. It is at least as effective as other anti­
inflam m atories such as diclofenac, ibuprofen, 
piroxicam and others.
Paracetamol has little anti-inflammatory activity, but 
is probably justifiably the most widely used analgesic 
medication it has a good safety profile, can be used as 
an antipyretic in febrile illnesses and is not an irritant to 
the gastric mucosa. It should be noted that with regular 
high doses (more than six tablets a day) analgesic 
rebound headache has been reported with paracetamol.
COX-2 inhibitors enjoyed tremendous popularity for 
several years, because o f the much reduced incidence 
o f gastric mucosal erosions and irritation even when 
gastroprotective strategies such as the use o f  proton 
pump inhibitors are used with NSAIDs.3 However, 
reports o f cardiac rhythm disturbances leading to 
unexpected deaths have led to a sharp downturn in their 
use. At present their routine use for chronic pain is 
controversial, although it has been only two agents in 
this class which were implicated.
Principle.
These drugs are the first choice and initial treatment for 
the vast majority o f pain syndromes. The most sensible 
approach to the use o f simple analgesics is to be very 
familiar with one or two common agents and to use 
them consistently, being aware o f all (even rare) 
adverse effects and interactions as well as contra­
indications. The vast array o f  duplicates available is 
confusing, especially when patients exhibit strong 
brand loyalties and display placebo effect. (“Panado 
works so much better than paracetamol” identical 
composition). A sympathetic but rational attitude is 
worth maintaining, not being needlessly rigid but at the 
same time not pandering to requests which may have 
harmful consequences (“if I re-prescribe her favourite 
medication I will at least get her off my back for the 
next month” must be a tempting thought for many 
practitioners).
Compound Analgesics.
Combinations o f simple analgesics with codeine are 
popular for use in moderately severe pain, and certainly 
have a place in acute pain, especially nociceptive type. 
The use o f compound medications in CHRONIC pain 
is discouraged, because o f the frequency o f drug 
interactions and adverse effects. In particular, 
paracetamol and codeine preparations with or without 
caffeine and an antihistamine or a muscle relaxant are 
likely to lead to unwanted rebound effects, sedation 
(resulting in patients taking analgesics for night 
sedation!) and impaired cognition.
Table I: Compound analgesics.
Combination Brand names
Paracetamol and codeine Panadeine, Cocodam ol,
Betapyn, Pynstop
Paracetamol, codeine, + Stopayne, G oldgesic
'muscle relaxant' (m eprobam ate)
Paracetamol and ‘muscle Besem ax, N orflex Co
relaxant' (antihistamine) (ophenadrine)
Aspirin and codeine Codis
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Principle.
The same general principle as for simple analgesics 
applies know one or two drugs well, and especially be 
aware o f drug interactions and adverse effects. In 
addition: at each time o f re-prescription ask yourself 
what the justification for continuing a compound 
analgesic drug long term is at this time. Tolerance and 
rebound pain as well as dependence are all commoner 
with compound analgesics preparations.
Opioids.
Medications containing a naturally derived or 
synnthetic opiod derivative, are the mainstay of 
medical management of chronic severe somatic pain, 
and are widely used in palliative care, but also for non- 
malignant pain.4 Despite their widespread use and
availability, it is surprising how frequently effective 
pain relief is not achieved. This usually relates to 
concerns by the prescriber that large doses may cause 
resp ira to ry  depression , dependence or other 
undesirable effects. Very often the role o f hospice to 
ensure that an adequate does is prescribed, and that any 
adverse effects that do occur are appropriately 
managed. The use of oral and other opioids in 
palliative care has become a specialised field and it is 
well worth soliciting expert assistance in patient care.
Because of their efficacy, it is tempting to use opioids 
for all types of severe pain, including neuropathic and 
psychogenic pain. In these categories the adverse 
effects may often outweigh the advantages, and 
especially for neurogenic pain opioids should be 
reserved as a last resort.
Table II: Opioid analgesics.
Drug Route Dose Comment
Codeine oral 30 -90 mg qid Under utilised for 
moderately severe acute 
pain. Usual adverse 
effects are constipation, 
nausea.
Dihydrocodeine (DHC) oral 30mg 4-6 hourly More effective than 
codeine. Often not 
available.
Dextropopoxyphene (Doxyol) oral 1-2 tabs 3 hourly Equivalent to DHC; 
sedation, dizziness, 
confusion common.
Morphine oral, IV, IM Very wide range, 
Usually start at 10- 
20mg 4 hourly oral
Constipation, nausea 
invariable, often needs to 
be given with an anti­
emetic and stool softener.
Pethidine IV/IM, (oral) 50-1 OOmg 4 hourly No advantage over 
morphine.
Tramadol oral 50-1 OOmg 4-6 hourly Equivalent to DHC.
Fentanyl IV/IM/transdermal
patch
60mg/day of oral 
morphine = 1mcg/hr 
of fentanyl patch
Equivalent to morphine, 
expensive. Patch avoids 
some Gl side effects, 
injections.
Different preparations, as usual, have distinct profiles 
of adverse effects:
c o n s t i p a t i o n  a n d  
a d d re s s e d .  In the
f r e q u e n t  n a u s e a  a r e  
c h ro n ic  s e t t in g  th e i r
Codeine (and dihydrocodeine) are favoured 
by neurosurgeons and others dealing with 
head injuries because they are more effective 
than simple analgesics and do not generally 
lead to impaired cognition and sedation 
(which could be confused with symptoms of 
complications of the injury). In this setting 
both drugs are very effective if  inevitable
effectiveness often declines rapidly, leading to 
tolerance and rebound pain.
• Dextro-propoxyphene is often used for severe 
chronic pain not responsive to compound 
analgesics, such as mechanical back pain or 
headache, but its use may lead to cognitive 
impairment (confusion or dizziness, even 
hallucinations), moderate pain because of the
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theoretical advantage that a combined mu 
receptor agonist and antagonist has, in being 
less susceptible to the development o f 
tolerance.
• M orphine in oral form, either tablets 
(including sustained release preparations) or 
as a syrup, is used in chronic nociceptive pain 
when other medications and modalities have 
not been effective. Its use is governed by 
adherence to the principles of upward titration 
and addressing adverse effects. Regular and 
frequent doses to prevent pain are often better 
than “as required” dosing.
•  Transdermal preparations (fantanyl and 
buprenorphine) in the form o f patches can 
g a s t r o - i n t e s t i n a l  s y m p to m s ,  but  are  
expensive.56
Principle.
In chronic severe somatic pain opioid drugs are the 
mainstay o f treatment, but their use is associated with 
significant adverse effects which must be anticipated 
and managed. Too often insufficient doses or too long 
dosing intervals render treatment inadequate titration 
to pain relief is the key. This may be achieved by 
monitored dose increases until therapeutic effect is 
reached, treating adverse effects as they arise or 
sometimes pre-emptively (e.g. constipation, nausea).
Neuropathic Pain.
When pain has burning or stabbing ('lancinating') 
qualities, it may be caused by damaged neural 
structures: peripheral nerve fibres, roots, dorsal 
ganglion cells, or central pathways (spinal, brainstem, 
thalamic or cort ical).  The dis t r ibu t ion and 
accompanying sysmptoms often help clarify the 
location o f the source.7 A significant number of patients
with hemisensory distribution of pain and other 
subjective phenomena (paraesthesia, feeling hot or 
cold) have no organic pathology and may be 
somatising, or 'amplifying' (e.g. chest and truncal pain 
with carpal tunnel syndrome) other symptoms. Pain 
may accompany acute injury (as with a foraminal 
intervertebral disc prolapse) or arise much later, when 
healing is already complete (as in post herpetic 
neuralgia).
The two classes of drugs conventionally used in this 
situation if  simple analgesics are unhelpful are tricyclic 
an t i cho l i ne rg ic s  ( am i tr ip ty l ine ,  imipramine ,  
nortriptyline) and anticonvulsants (carbamazepine, 
phenytoin, gabapentin, lamotrigine).8 Both o f these 
groups were originally used for other indications and 
have considerable adverse effects, often dose-limiting. 
The newer anticonvulsants, such as gabapentin and 
more recently pregabilin and lamotrigine, have fewer 
adverse effects and thus higher doses are tolerated. 
They have become a first choice for clinicians treating 
neuropathic pain where they are available.9
In general, the tricyclic drugs and derivatives tend to 
be more effective for diffuse burning pain which is 
poorly localised (as in “burning feet” of painful 
peripheral neuropathy), whilst anticonvulsants are 
more useful in the very localised sharp “lancinating” 
pain with shooting qualities in a specific radiation of 
particular nerve or root irritation/compression (for 
example in trigeminal neuralgia). In addition central 
pain syndromes, for example after a thalamic stroke, 
may also respond o anticonvulsants.
After peripheral or plexus injuries intractable pain 
with skin and skeletal changes (complex regional pain 
syndrome) may result. Treatment with medications is 
often frustrating, and a combined approach with 
regional and central blocks and consideration of 
neurosurgical procedures (such as dorsal root entry 
zone stimulation) should be undertaken.10
Table III:
Drug Route Dose Drug class Comment
Amitriptyline Oral 12.5 mg nocte tricyclic Slow upward titration, expect
- 150mg nocte transient drowsiness.
Imipramine
(Nortiptyiine)
Oral 25 mg daily - tricyclic Less sedating, less effective.
Dothiepin Oral 25 mg nocte - tricyclic Similar to imipramine.
Duloxetine Oral 30 - 60 mg new tricyclic New combined anticholinergic, and
twice daily derivative anti-adrenergic, used in diabetic 
neuropathy.
Carbamazepine Oral 100 mg nocte - 
400 mg tds
anticonvulsant Drowsiness, ataxia often limit dose.
Phenytoin Oral 100mg nocte- anticonvulsant More side effects than carbamazepine,
200 mg bd sometimes useful in combination.
Gabapentin Oral 100 mg nocte- anticonvulsant As effective as carbamazepine, higher
(Neurontin) 900 mg tds doses tolerated, first choice when 
Available.
Pregabalin Oral 150-600 mg anticonvulsant Licensed in USA for diabetic
(Lyrica) daily (50-200 
200 mg tds
neuropathic pain, less sedating.
Lamotrigine Oral 50 mg daily to 
200 mg bd
anticonvulsant Very little sedation, effective.
Lignocaine Topical local anaesthetic Limited use in post herpetic pain.
Patch
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Principle.
Older drugs generally have more side effects but are 
more available and cheaper. Use what is available and 
abandon older drugs when side effects (especially 
sedation and ataxia, but not forgetting to ask about 
hallucinations, reduced libido and incontinence) are 
unacceptable. Most medications in these classes 
should be started at low doses and increased very 
slowly, over weeks. An example would be 
amitryptiline for painful neuropathy: 10 or 12.5mg at 
night for one week, 25mg at night for one week, 50mg 
at night for one week. If there is insufficient pain relief 
on 50mg: give 75mg for two weeks, and lOOmg for two 
weeks. If  un acceptable side effects stay on lower dose 
for longer before increasing.
M igraine: A Special Case.
Many people with chronic pain have headache, which 
may be quite intractable and present for years. A large 
proportion o f these have frequent or chronic migraine,'1 
and because medications for migraine prophylaxis and 
treatment are specific to the condition, a brief 
discussion follows.
1. As always, the most accurate and complete 
diagnosis possible is the first step. Many 
headache sufferers have mixed headaches, 
with chronic tension type and analgesic 
rebound components as well as migrainous 
elements.
Table IV:
Drug Dose Drug Class Effectiveness Comment
Propranolol* 20 - 160mg Beta blocker ++++ Very effective. Avoid in asthma,
tds (80-720mg peripheral arterial disease. May cause
daily of long 
acting prep.)
depression, insomnia.
Amitriptyline 25 - 100mg Tricyclic +++ Effective, especially if tension type
node anticholinergic headache also present. Sedating. 
Cognitive side effects in elderly 
(Avoid over 65).
Valproate* 200-500mg Anticonvulsant +++ Effedive, sedating. May cause weight
tds gain, hair loss.
Flunnarizine 80 mg daily Calcium channel ++ No randomised control trial evidence,
(Sibelium) antagonist but few side effects.
Topiramate* 25-100mg bd Novel ++++ Effective, but difficult to use with +
[13] anticonvulsant side effects.
Levetiracetam 500-1 OOOmg Novel ++++ Preliminary evidence good, 
Expensive.
2. Migraine management includes avoiding or 
minimising precipitants, abortive treatment 
for individual headaches, and prophylaxis. 
Abortive treatment may consist o f simple 
analgesics including anti-inflammatories, 
ergotamine derivatives or triptans, often with 
and anti-emetic. Often a stepwise progression 
is advocated: if  a simpler medication is 
effective the next step is necessary.
3. Prophylactic treatment is advised when 
headaches are very frequent and/or disabling 
this does vary with individual sufferers.12 Two 
or more disabling m igraines a m onth 
(sufficient to prevent sufferers from attending 
work or school) is a reasonable rule o f thumb 
in  i n t e r m i t t e n t  m i g r a i n e ,  b u t  in  
chronic/transform ed m igraine individual 
headaches are usually less severe and 
indications are less clear-cut.
Principle.
Once the diagnosis and requirement for prophylaxis are 
clear, treatment for migraine should be aggressive, 
with clear monitoring (by the use o f headache diaries) 
and treatment goals. There is usually a trade-off 
between therapeutic and adverse effects. This should 
be negotiated with the patient, taking into account the 
tendency form many cognitive and drowsiness-related 
side effects to attenuate overtime.
Many other medications have been used, for example 
other beta blockers, other tricyclics and herbal
remedies. Solid evidence for efficacy is available for 
those marked*.
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Conclusion
When confronted by a patient with chronic pain, and
planning medications, there is indubitable merit in
having a clear approach. It is useful for the prescriber to
ask himself or herself some questions:
1. What am I treating (What is the diagnosis, 
what type o f pain is this?).
2. Is there appropriate non-pharmacological 
trea tm ent that  should  be considered? 
(including psychological, physical, nerve 
blocks, surgery)?
3. What class o f medications is most suitable?
4. Where is the patient in terms o f what 
(appropriate or inappropriate) medications 
and other treatments he has previously 
received?
5. Which adverse effects can be anticipated for 
the planned treatment?
6. What is the limit for adverse effects for this 
patient and this treatment?
7. How will I measure effectiveness and 
adverse effects?
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